Optimi Health Corp. (OPTH) Form 6-K — Jun 16, 2026
Optimi Health Corp. announced the production completion of two standardized microdose psilocybin finished drug products formulated at 1 mg and 2 mg dosages. These naturally derived products are designed to provide clinical research organizations with the consistent, validated doses required for controlled studies. The new formats extend the company's psilocybin range, which already includes a 5 mg capsule formulation currently commercially prescribed for treatment-resistant depression in Australia.
Key figures
- New product dosages mg
- [1,2]
- Existing product dosage mg
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.